Table 1 The main characteristics of included studies
Disease | Patient-controlled epidural analgesia (PCEA) | Patient-controlled intravenous analgesia (PCIA) | ||||||
|---|---|---|---|---|---|---|---|---|
N(M/F) | Average age | Drugs | POC | N(M/F) | Average age | Drugs | ||
Joshua 2013 [18] | AIS | 44 | NM | Bupivacaine Fentanyl | 5 cm up to the middle of fused centrum | 22 | NM | Morphine |
Kluba 2010 [19] | IDD | 29 (14/15) | 57 | Ropivacaine Sufentanil | 3 cm up to the middle of fused centrum | 23 (14/9) | 62 | Piritramid |
Gauger 2009 [17] | AIS | 19 (0/19) | 15.1 | Bupivacaine Hydromorphone | 3–5 cm up to middle of fused centrum | 19 (4/15) | 14.7 | Hydromorphone |
Schenk 2006 [23] | LS | 28 (15/13) | 42 | Ropivacaine Sufentanil | At the middle of fused centrum | 30 (21/9) | 50 | Morphine |
Fisher 2003 [22] | IDD | 36 (17/19) | 50 | Fentanyl Bupivacaine Epivacaine | 10 cm up to the middle of fused centrum | 38 (15/23) | 51 | Fentanyl |
Cassady 2000 [20] | AIS | 17 (2/15) | 14.6 | Bupivacaine Epivacaine | NM | 16 (3/13) | 14.4 | Morphine sulfate |
Coben 1997 [21] | IDD | 21 | 45 | Morphine sulfate | NM | 21 | 45 | Morphine sulfate Bupivacaine |
Johnson 1989 [24] | IDD | 29 (21/8) | 39 | Fentanil Morphine sulfate | 2–3 cm up to middle of fused centrum | 13 (8/5) | 39 | Morphine sulfate |